Diego Cadavid to Natalizumab
This is a "connection" page, showing publications Diego Cadavid has written about Natalizumab.
Connection Strength
0.315
-
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdov? EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 05; 17(5):405-415.
Score: 0.153
-
Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
Score: 0.107
-
Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013 Dec; 19(14):1826-40.
Score: 0.028
-
Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87.
Score: 0.026